Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2009-11-11
2011-11-22
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S407000, C544S370000, C548S305100
Reexamination Certificate
active
08063053
ABSTRACT:
The invention relates to 1-(arylsulfonyl)-4-(piperazin-1-yl)-1H-benzimidazole compounds of the Formula I:or a tautomer, stereoisomer, or pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.
REFERENCES:
patent: 5849759 (1998-12-01), Arnaiz et al.
patent: 5990105 (1999-11-01), Bos et al.
patent: 6251893 (2001-06-01), Maddaford et al.
patent: 6255306 (2001-07-01), Macor
patent: 6288103 (2001-09-01), Faull et al.
patent: 6316450 (2001-11-01), Bromidge et al.
patent: 6380199 (2002-04-01), Reavill et al.
patent: 6423717 (2002-07-01), Bromidge et al.
patent: 6559167 (2003-05-01), Garst et al.
patent: 7034029 (2006-04-01), Kelly et al.
patent: 7087750 (2006-08-01), Caldirola et al.
patent: 7282495 (2007-10-01), Kelly et al.
patent: 2002/0165251 (2002-11-01), Caldirola et al.
patent: 2004/0192749 (2004-09-01), Kelly et al.
patent: 2006/0069094 (2006-03-01), Bonhaus et al.
patent: 0930302 (1999-07-01), None
patent: 9603400 (1996-02-01), None
patent: 9827081 (1998-06-01), None
patent: 9902502 (1999-01-01), None
patent: 9965906 (1999-12-01), None
patent: 0208178 (2002-01-01), None
patent: 0232863 (2002-04-01), None
patent: WO 02/36562 (2002-05-01), None
patent: WO 02/102774 (2002-12-01), None
patent: WO 03/026664 (2003-04-01), None
patent: WO 2004/035740 (2004-04-01), None
patent: WO 2005/112938 (2005-12-01), None
patent: WO 2006/015259 (2006-02-01), None
Robichaud et al. In Annual Reports in Medicinal Chemistry, vol. 36, p. 11-20 (2000).
Rogers et al. Psychopharmacology, vol. 158, p. 114-119 (2001).
Mahmood et al., “Bicyclic heteroarylpiperazines as selective brain penetrant 5-HT6receptor antagonists”Bioorganic&Medicinal Chemistry Lettersvol. 15, No. 21 (2005) pp. 4867-4871.
Holenz et al., “Medicinal chemistry strategies to 5-HT6receptor ligands as potential cognitive enhancers and antiobesity agents”Drug Discovery Todayvol. 11 No. 7-8 (2006) pp. 283-299.
Holenz, J., et al., “Medicinal Chemistry Strategies to 5-HT6Receptor Ligands as Potential Cognitive Enhancer and Antiobesity Agents”, Drug Discovery Today, 2006, pp. 283-299, vol. 11, Appendix 1.
Routledge, C., et al., “Characterization of SB-271046: A Potent, Selective and Orally Active 5-HT6Receptor Antagonist”, British Journal of Pharmacology, 2000, pp. 1606-1612, vol. 130, Appendix 2.
Mitchell, E., et al., “5-HT6Receptors: A Novel Target for Cognitive Enhancements”, Pharmacology & Therapeutics, 2005, pp. 320-333, vol. 108, Appendix 3.
Schechter, L. E., et al., “Neuropharmacological Profile of Novel and Selective 5-HT6Receptor Agonists: WAY-181187 and WAY-208466”, Neuropsychopharmacology, 2008, pp. 1323-1335, vol. 33, Appendix 4.
Pullagurla, M., et al., “Modulation of the Stimulus Effects of (+) amphetamine by the 5-HT6 Antagonist MS-245”, Pharmacology, Biochemistry and Behavior, 2004, pp. 263-268, vol. 78, Appendix 5.
Messina, et al., “Association of the 5-HT6Receptor Gene Polymorphism C267T with Parkinson's Disease”, Neurology, 2002, pp. 828-829, vol. 58, Appendix 6.
Ernst, M., et al., “DOPA Decarboxylase Activity in Attention Deficit Hyperactivity Disorder Adults. A [Fluorine-18]Fluorodopa Positron Emission Tomographic Study”, The Journal of Neuroscience, 1998, pp. 5901-5907, vol. 18, Appendix 8.
CAS STN Registry entry No. 1028268-34-9; entered Jun. 15, 2008.
CAS STN Registry entry No. 1027325-53-6; entered Jun. 11, 2008.
CAS STN Registry entry No. 1027222-67-8; entered Jun. 11, 2008.
CAS STN Registry entry No. 1026749-96-1; entered Jun. 9, 2008.
CAS STN Registry entry No. 1025813-79-9; entered Jun. 5, 2008.
Chalmers, et al., TiPs, vol. 17, pp. 166-172, (Apr. 1996).
Methvin, Isaac et al., Bioorganic & Medicinal Chemistry Letters, vol. 10, pp. 1719-1721, (2000).
Russell, M.G., et al., Curr. Top. Med. Chem., vol. 2, No. 6, pp. 643-654, (Jun. 2002).
Andrae Patrick Michael
Haydar Simon Nicolas
Robichaud Albert Jean
Yun Heedong
Bernhardt Emily
Kispert Jennifer A.
Wyeth LLC
LandOfFree
1-(arylsulfonyl)-4-(piperazin-1-yl)-1H-benzimidazoles as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1-(arylsulfonyl)-4-(piperazin-1-yl)-1H-benzimidazoles as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1-(arylsulfonyl)-4-(piperazin-1-yl)-1H-benzimidazoles as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4280601